Table 2 Total number of patients (%) with any adverse event and decrease in platelet
| Â | Â | Adverse events number of patients (%) | Percentage decrease in platelet number of patients (%) | ||||
|---|---|---|---|---|---|---|---|
Part |  Treatment group (N) | Any AE | Any AE (days 1–28) | 25 to 38% | 39 to 51% | 52 to 85% | All |
A | 0.03/0.06 mg/kg IV (N = 4)a | 2 (50) | 1 (25) | 0 | 0 | 0 | 0 |
| Â | 0.3 mg/kg IV (N = 8)a | 2 (25) | 2 (25) | 1 (13%) | 0 | 0 | 1 (13%) |
| Â | 3 mg/kg IV (N = 12) | 7 (58) | 5 (42) | 6 (50%) | 0 | 0 | 6 (50%) |
| Â | 10 mg/kg IV (N = 12) | 6 (50) | 5 (42) | 4 (33%) | 0 | 1 (8%) | 5 (42%) |
| Â | 20 mg/kg IV (N = 6) | 5 (83) | 4 (67) | 2 (33%) | 2 (33%) | 0 | 4 (67%) |
| Â | 30 mg/kg IV (N = 6) | 4 (67) | 3 (50) | 1 (17%) | 2 (33%) | 0 | 3 (50%) |
B | 6 mg/kg repeat IV (N = 37) | 15 (41) | 8 (22) | 10 (27%) | 4 (11%) | 1 (3%) | 15 (41%) |
C | 500 mg SC (N = 12) | 6 (50) | 6 (50) | 5 (42%) | 2 (17%) | 0 | 7 (58%) |
Pooled (Parts A, B, C) | All Placebo (N = 38) | 12 (32) | 8 (21) | 8 (21%) | 1 (3%) | 1 (3%) | 10 (26%) |